MiR-378は,ミトゲン活性化タンパク質キナーゼ経路因子の結合抑制により,心筋縮を制御する
Jayavarshni Ganesan1, Deepak Ramanujam, Yassine Sassi
1Institut für Pharmakologie und Toxikologie, Technische Universität München, Munich, Germany.
Circulation
|April 30, 2013
まとめ
マイクロRNA-378 (miR-378) は,MAPK経路を標的にすることで,心筋縮を抑制する. 疾患モデルにおけるmiR-378の復元により,高縮が著しく低下し,心臓の機能が改善され,治療の可能性が示唆されています.
科学分野:
- 心臓病学 心臓病学
- 分子生物学は分子生物学である.
- バイオケミストリー バイオケミストリー
背景:
- マイクロRNAは心臓における遺伝子発現を調節し,心疾患と関連した不調が起こります.
- マイクロRNA-378 (miR-378) は心臓で高い濃度で発現しますが,主にがんで研究されています.
研究 の 目的:
- kardiomyocyte hypertrophyを調節する miR-378の役割を調査する.
- 心臓病におけるmiR-378の治療の可能性を調査する.
主な方法:
- 単離された一次性心筋細胞と in vivo 圧力過負荷モデル (胸腔大動脈収縮) を利用した.
- 生物情報学的予測,mRNA/タンパク質分析,およびルシフェラーゼアッセイを用いて,miR-378の標的を特定した.
- 心筋細胞を標的としたmiR-378の復元のためにアデノ関連ウイルス媒介の遺伝子配送を使用した.
主要な成果:
- miR-378は,心筋細胞高縮を抑制するのに必要で十分であった.
- ミトゲン活性化タンパク質キナーゼ (MAPK) 経路の4つの重要なコンポーネントを直接のmiR-378標的として検証しました.
- in vivoでmiR-378を復元すると,心筋縮が著しく軽減され,心機能が改善されます.
結論:
- miR-378は,MAPKシグナル伝達経路を抑制することによって,心筋細胞高縮の重要な調節剤として作用します.
- 心筋細胞を標的としたmiR-378の復元は,心筋疾患の潜在的な治療戦略を示しています.
関連する概念動画
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:23Master Transcription Regulators
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:26Cellular Adaptation II: Hypertrophy
Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...